The detection of cutaneous melanoma still largely relies on clinical suspicion, skin biopsy,
and histopathologic evaluation. New technologies are being evaluated to bypass the skin
biopsy in the detection of melanoma. The quest for reliable biomarkers, with respect to
subclinical detection, prognosis, and predicting treatment response, is longstanding and
ongoing. New therapies have been developed for metastatic disease, including targeted
small molecule inhibitors as well as immune modulators.
Semin Cutan Med Surg 31:45-49 © 2012 Elsevier Inc. All rights reserved.